MedTrace Logo

A Study of HM11260C in Healthy Male Subject

NCT01093729 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2014-02-07

No results posted yet for this study

Summary

Study Design: Randomized, double-blind, placebo-controlled, escalating single-dose design. Five ascending dose cohorts are planned.

Conditions

  • Healthy

Interventions

DRUG

HM11260C

HM11260C 0.5mcg/kg or Placebo

DRUG

HM11260C

HM11260C 2mcg/kg or Placebo

DRUG

HM11260C

HM11260C 4mcg/kg or Placebo

DRUG

HM11260C

HM11260C 8mcg/kg or Placebo

DRUG

HM11260C

HM11260C 14mcg/kg or Placebo

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Hanmi Clinical · Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-10-31
Completion
2010-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01093729 on ClinicalTrials.gov